Works matching IS 17762596 AND DT 2023 AND VI 18 AND IP 2

Results: 12

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.
Published in:
Targeted Oncology, 2023, v. 18, n. 2, p. 235, doi. 10.1007/s11523-023-00954-w
By:
- Piejko, Karolina;
- Cybulska-Stopa, Bożena;
- Ziętek, Marcin;
- Dziura, Robert;
- Galus, Łukasz;
- Kempa-Kamińska, Natasza;
- Ziółkowska, Barbara;
- Rutkowska, Ewa;
- Kopciński, Tomasz;
- Kubiatowski, Tomasz;
- Bal, Wiesław;
- Suwiński, Rafał;
- Mackiewicz, Jacek;
- Kamińska-Winciorek, Grażyna;
- Czarnecka, Anna M.;
- Rutkowski, Piotr
Publication type:
Article
Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study
Published in:
Targeted Oncology, 2023, v. 18, n. 2, p. 209, doi. 10.1007/s11523-023-00956-8
By:
- Ishihara, Hiroki;
- Nemoto, Yuki;
- Nakamura, Kazutaka;
- Tachibana, Hidekazu;
- Ikeda, Takashi;
- Fukuda, Hironori;
- Yoshida, Kazuhiko;
- Kobayashi, Hirohito;
- Iizuka, Junpei;
- Shimmura, Hiroaki;
- Hashimoto, Yasunobu;
- Kondo, Tsunenori;
- Takagi, Toshio
Publication type:
Article
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Published in:
Targeted Oncology, 2023, v. 18, n. 2, p. 221, doi. 10.1007/s11523-023-00953-x
By:
- Rimini, Margherita;
- Persano, Mara;
- Tada, Toshifumi;
- Suda, Goki;
- Shimose, Shigeo;
- Kudo, Masatoshi;
- Cheon, Jaekyung;
- Finkelmeier, Fabian;
- Lim, Ho Yeong;
- Presa, José;
- Masi, Gianluca;
- Yoo, Changhoon;
- Lonardi, Sara;
- Piscaglia, Fabio;
- Kumada, Takashi;
- Sakamoto, Naoya;
- Iwamoto, Hideki;
- Aoki, Tomoko;
- Chon, Hong Jae;
- Himmelsbach, Vera
Publication type:
Article
Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence.
Published in:
Targeted Oncology, 2023, v. 18, n. 2, p. 287, doi. 10.1007/s11523-023-00952-y
By:
- Fung, Simon;
- Blair, Hannah A.
Publication type:
Article
Selinexor–Bortezomib–Dexamethasone: A Review in Previously Treated Multiple Myeloma.
Published in:
Targeted Oncology, 2023, v. 18, n. 2, p. 303, doi. 10.1007/s11523-022-00945-3
By:
- Syed, Yahiya Y.
Publication type:
Article
Relugolix: A Review in Advanced Prostate Cancer.
Published in:
Targeted Oncology, 2023, v. 18, n. 2, p. 295, doi. 10.1007/s11523-022-00944-4
By:
- Shirley, Matt
Publication type:
Article
Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
Published in:
Targeted Oncology, 2023, v. 18, n. 2, p. 247, doi. 10.1007/s11523-023-00951-z
By:
- Lee, Nuri;
- Lee, Jae Lyun;
- Lee, Ju-Yeun
Publication type:
Article
First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors.
Published in:
Targeted Oncology, 2023, v. 18, n. 2, p. 181, doi. 10.1007/s11523-023-00948-8
By:
- Harding, James J.;
- Jungels, Christiane;
- Machiels, Jean-Pascal;
- Smith, David C.;
- Walker, Chris;
- Ji, Tao;
- Jiang, Ping;
- Li, Xin;
- Asatiani, Ekaterine;
- Van Cutsem, Eric;
- Abou-Alfa, Ghassan K.
Publication type:
Article
Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.
Published in:
2023
By:
- Popat, Sanjay;
- Ahn, Myung-Ju;
- Ekman, Simon;
- Leighl, Natasha B.;
- Ramalingam, Suresh S.;
- Reungwetwattana, Thanyanan;
- Siva, Shankar;
- Tsuboi, Masahiro;
- Wu, Yi-Long;
- Yang, James Chih-Hsin
Publication type:
Correction Notice
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich<sup>LMU</sup> Molecular Tumor Board.
Published in:
Targeted Oncology, 2023, v. 18, n. 2, p. 257, doi. 10.1007/s11523-023-00950-0
By:
- Dorman, Klara;
- Zhang, Danmei;
- Heinrich, Kathrin;
- Reeh, Laurens;
- Weiss, Lena;
- Haas, Michael;
- Beyer, Georg;
- Rössler, Daniel;
- Goni, Elisabetta;
- Renz, Bernhard W.;
- D'Haese, Jan G.;
- Kunz, Wolfgang G.;
- Seidensticker, Max;
- Corradini, Stefanie;
- Niyazi, Maximilian;
- Ormanns, Steffen;
- Kumbrink, Jörg;
- Jung, Andreas;
- Klauschen, Frederick;
- Werner, Jens
Publication type:
Article
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Published in:
Targeted Oncology, 2023, v. 18, n. 2, p. 269, doi. 10.1007/s11523-023-00949-7
By:
- Caligiuri, Maureen;
- Williams, Grace L.;
- Castro, Jennifer;
- Battalagine, Linda;
- Wilker, Erik;
- Yao, Lili;
- Schiller, Shawn;
- Toms, Angela;
- Li, Ping;
- Pardo, Eneida;
- Graves, Bradford;
- Azofeifa, Joey;
- Chicas, Agustin;
- Herbertz, Torsten;
- Lai, Maria;
- Basken, Joel;
- Wood, Kenneth W.;
- Xu, Qunli;
- Guichard, Sylvie M.
Publication type:
Article
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
Published in:
Targeted Oncology, 2023, v. 18, n. 2, p. 195, doi. 10.1007/s11523-023-00946-w
By:
- Hsu, Ping-Chih;
- Lee, Suey-Haur;
- Chiu, Li-Chung;
- Lee, Chung-Shu;
- Wu, Chiao-En;
- Kuo, Scott Chih-Hsi;
- Ju, Jia-Shiuan;
- Huang, Allen Chung-Cheng;
- Li, Shih-Hong;
- Ko, Ho-Wen;
- Yang, Cheng-Ta;
- Wang, Chin-Chou
Publication type:
Article